Workflow
HVSEN BIOTECH(300871)
icon
Search documents
回盛生物(300871) - 关于“回盛转债”赎回实施暨即将停止交易的重要提示性公告
2025-05-14 10:04
| 证券代码:300871 | 证券简称:回盛生物 | 公告编号:2025-053 | | --- | --- | --- | | 转债代码:123132 | 转债简称:回盛转债 | | 武汉回盛生物科技股份有限公司 关于"回盛转债"赎回实施暨即将停止交易的重要提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、 误导性陈述或重大遗漏。 截至 2025 年 5 月 14 日收市后,距离回盛转债停止交易日(2025 年 5 月 16 日)仅剩下 1 个交易日,距离回盛转债赎回日(2025 年 5 月 21 日)仅剩 4 个交易日。 3、投资者若转股,需开通创业板交易权限。投资者不符合创业板股票适 当性管理要求的,不能将所持回盛转债转换为股票,特提请投资者关注不能转 股的风险。 重要内容提示: 1、最后交易日:2025 年 5 月 15 日 2025 年 5 月 15 日为回盛转债最后一个交易日;当日回盛转债简称为"Z 盛转债";2025 年 5 月 15 日收市后回盛转债将停止交易。 2、最后转股日:2025 年 5 月 20 日 2025 年 5 月 20 日是回盛转债最后一个 ...
回盛生物(300871) - 关于“回盛转债”赎回实施暨即将停止交易的重要提示性公告
2025-05-13 08:06
| 证券代码:300871 | 证券简称:回盛生物 | 公告编号:2025-052 | | --- | --- | --- | | 转债代码:123132 | 转债简称:回盛转债 | | 武汉回盛生物科技股份有限公司 关于"回盛转债"赎回实施暨即将停止交易的重要提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示: 1、最后交易日:2025 年 5 月 15 日 2025 年 5 月 15 日为回盛转债最后一个交易日;当日回盛转债简称为"Z 盛转债";2025 年 5 月 15 日收市后回盛转债将停止交易。 2、最后转股日:2025 年 5 月 20 日 2025 年 5 月 20 日是回盛转债最后一个转股日,当日收市前,持有回盛转 债的投资者仍可进行转股;2025 年 5 月 20 日收市后,未转股的回盛转债将停 止转股,剩余可转换公司债券(以下简称"可转债")将按照 100.64 元/张(含 税)的价格被强制赎回。若被强制赎回,投资者可能面临投资损失。 截至 2025 年 5 月 13 日收市后,距离回盛转债停止交易日(2025 年 5 ...
回盛生物(300871) - 关于“回盛转债”赎回实施暨即将停止交易的重要提示性公告
2025-05-12 12:06
| 证券代码:300871 | 证券简称:回盛生物 | 公告编号:2025-051 | | --- | --- | --- | | 转债代码:123132 | 转债简称:回盛转债 | | 武汉回盛生物科技股份有限公司 关于"回盛转债"赎回实施暨即将停止交易的重要提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示: 1、最后交易日:2025 年 5 月 15 日 2025 年 5 月 15 日为回盛转债最后一个交易日;当日回盛转债简称为"Z 盛转债";2025 年 5 月 15 日收市后回盛转债将停止交易。 2、最后转股日:2025 年 5 月 20 日 2025 年 5 月 20 日是回盛转债最后一个转股日,当日收市前,持有回盛转 债的投资者仍可进行转股;2025 年 5 月 20 日收市后,未转股的回盛转债将停 止转股,剩余可转换公司债券(以下简称"可转债")将按照 100.64 元/张(含 税)的价格被强制赎回。若被强制赎回,投资者可能面临投资损失。 截至 2025 年 5 月 12 日收市后,距离回盛转债停止交易日(2025 年 5 ...
回盛生物(300871) - 关于提前赎回“回盛转债”的第十四次提示性公告
2025-05-12 08:36
| 证券代码:300871 | 证券简称:回盛生物 | 公告编号:2025-050 | | --- | --- | --- | | 转债代码:123132 | 转债简称:回盛转债 | | 武汉回盛生物科技股份有限公司 关于提前赎回"回盛转债"的第十四次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、 误导性陈述或重大遗漏。 特别提示: 1、可转债赎回条件满足日:2025 年 4 月 17 日 2、可转债赎回登记日:2025 年 5 月 20 日 3、可转债赎回日:2025 年 5 月 21 日 7、发行人赎回资金到账日(到达中登公司):2025 年 5 月 26 日 8、投资者赎回款到账日:2025 年 5 月 28 日 9、赎回类别:全部赎回 10、根据安排,截至 2025 年 5 月 20 日(赎回登记日)收市后仍未转股的 回盛转债,将按 100.64 元/张(含税)的价格强制赎回。回盛转债二级市场价 格与赎回价格存在较大差异,特提醒回盛转债持有人注意在限期内转股。 11、投资者不符合创业板股票适当性管理要求的,不能将所持回盛转债转 换为股票,特提请投资者关注不能转股的 ...
2025年第19周周报:它博会归来,如何看宠物经济发展新趋势?
Tianfeng Securities· 2025-05-12 00:30
Investment Rating - Industry Rating: Outperform the market (maintained rating) [12] Core Views - The pet sector continues to show high prosperity, driven by domestic substitution and consumption upgrades, leading to a dual increase in volume and price [1][2] - The industry is transitioning from "scale expansion" to "value creation," with leading companies shifting from "manufacturing" to "intelligent manufacturing" through formula innovation and precise demand capture [2][17] - The domestic pet food market remains strong, with a significant increase in sales and exports, indicating robust growth potential for domestic brands [2][17] Summary by Sections Pet Sector - The fifth TOPS Pet Expo in Shanghai showcased over 1,200 exhibitors and 8,000+ brands, reflecting strong growth momentum in the pet industry, with a 43% year-on-year increase in attendance [1][16] - Trends in pet food are shifting towards precision nutrition, with a focus on age-specific feeding and high-end production techniques [1][16] - Key recommended companies in the pet food sector include Guibao Pet, Zhongchong Co., Petty Co., and Lusi Co., with additional recommendations for pet medical and product companies [2][17] Swine Sector - As of May 10, the average price of live pigs was 14.90 yuan/kg, showing a slight decline, with production capacity continuing to grow [3][18] - The industry is facing a potential downturn in profitability due to weak demand and seasonal price declines [3][19] - Recommended companies include leading players such as Wens Foodstuffs and Muyuan Foods, with a focus on core assets [19] Poultry Sector - The white chicken segment is facing uncertainties in breeding imports, with a significant decline in the number of breeding stock updated [20][21] - The yellow chicken segment is expected to benefit from improved consumer demand, with stable prices observed [23] - Recommended companies include Shengnong Development and Lihua Co. for white chicken, and Wens Foodstuffs for yellow chicken [22][23] Planting Sector - The government emphasizes agricultural technology innovation and self-sufficiency in food security, with a focus on biological breeding [25][26] - Recommended companies in the seed sector include Longping High-Tech and Dabeinong, with additional focus on agricultural water-saving technologies [25][26] Feed and Animal Health Sector - Hai Da Group is highlighted for its market share growth and consistent performance in the feed sector [27] - The animal health sector is seeing new opportunities in pet health products, with recommended companies including KQ Bio and Zhongmu Co. [28]
回盛生物: 关于提前赎回“回盛转债”的第十三次提示性公告
Zheng Quan Zhi Xing· 2025-05-09 08:39
Core Viewpoint - Wuhan Huirong Biological Technology Co., Ltd. has announced the mandatory redemption of its convertible bonds at a price of 100.64 yuan per bond, urging bondholders to convert their bonds into shares within the specified period due to significant differences between the market price and the redemption price [1][2] Group 1: Convertible Bond Overview - The company issued 7 million convertible bonds on December 17, 2021, with a total amount of 70 million yuan and a maturity of 6 years [2] - The initial conversion price was set at 28.32 yuan per share, which was adjusted to 27.99 yuan per share after the 2021 annual equity distribution [2][4] - The conversion price has undergone several adjustments, with the latest being 15.00 yuan per share as of August 2024 [6][7] Group 2: Redemption Conditions - The mandatory redemption was triggered as the company's stock price met the condition of being at least 130% of the conversion price (19.50 yuan) for at least 15 trading days within a 30-day period [1][7] - The redemption price is calculated to be 100.64 yuan per bond, which includes accrued interest [8] Group 3: Redemption Process - The redemption will be executed for all bondholders registered with the China Securities Depository and Clearing Corporation by May 20, 2025 [9] - The company will publish announcements regarding the redemption results and the delisting of the convertible bonds from the Shenzhen Stock Exchange [9] Group 4: Management Transactions - During the six months prior to the redemption conditions being met, the company's senior management reduced their holdings of the convertible bonds from 21,120 to 60 bonds [10]
回盛生物(300871) - 关于提前赎回“回盛转债”的第十三次提示性公告
2025-05-09 07:40
| 证券代码:300871 | 证券简称:回盛生物 | 公告编号:2025-049 | | --- | --- | --- | | 转债代码:123132 | 转债简称:回盛转债 | | 武汉回盛生物科技股份有限公司 关于提前赎回"回盛转债"的第十三次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、 误导性陈述或重大遗漏。 特别提示: 1、可转债赎回条件满足日:2025 年 4 月 17 日 2、可转债赎回登记日:2025 年 5 月 20 日 3、可转债赎回日:2025 年 5 月 21 日 4、可转债赎回价格:100.64 元/张(含息税) 5、可转债停止交易日:2025 年 5 月 16 日 6、可转债停止转股日:2025 年 5 月 21 日 公司于 2025 年 4 月 17 日召开第三届董事会第二十一次会议,审议通过了 《关于提前赎回"回盛转债"的议案》,同意公司行使提前赎回的权利。现将 提前赎回"回盛转债"的有关事项公告如下: 一、可转债基本情况 (一)可转债发行上市情况 7、发行人赎回资金到账日(到达中登公司):2025 年 5 月 26 日 8、投资者赎回 ...
回盛生物(300871) - 关于提前赎回“回盛转债”的第十二次提示性公告
2025-05-08 09:16
| 证券代码:300871 | 证券简称:回盛生物 | 公告编号:2025-048 | | --- | --- | --- | | 转债代码:123132 | 转债简称:回盛转债 | | 武汉回盛生物科技股份有限公司 关于提前赎回"回盛转债"的第十二次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、 误导性陈述或重大遗漏。 特别提示: 1、可转债赎回条件满足日:2025 年 4 月 17 日 2、可转债赎回登记日:2025 年 5 月 20 日 3、可转债赎回日:2025 年 5 月 21 日 4、可转债赎回价格:100.64 元/张(含息税) 5、可转债停止交易日:2025 年 5 月 16 日 6、可转债停止转股日:2025 年 5 月 21 日 7、发行人赎回资金到账日(到达中登公司):2025 年 5 月 26 日 10、根据安排,截至 2025 年 5 月 20 日(赎回登记日)收市后仍未转股的 回盛转债,将按 100.64 元/张(含税)的价格强制赎回。回盛转债二级市场价 格与赎回价格存在较大差异,特提醒回盛转债持有人注意在限期内转股。 11、投资者不符合创业板 ...
回盛生物(300871) - 2025年5月7日投资者关系活动记录表
2025-05-07 11:30
Financial Performance - In 2024, the company achieved operating revenue of CNY 1.2 billion, a year-on-year increase of 17.71% [2] - The net profit attributable to shareholders was -CNY 20.16 million, a decline of 220.11% year-on-year [2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -CNY 16.24 million, down 45.06% year-on-year [2] - In Q1 2025, the company reported operating revenue of CNY 399 million, a year-on-year growth of 92.96% [2] - The net profit attributable to shareholders in Q1 2025 was CNY 44.50 million, an increase of 371.23% year-on-year [2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 34.09 million, up 511.54% year-on-year [2] Strategic Development - The company focuses on technological innovation as a driving force for development, with a vertical layout in the upstream raw material drug industry and a horizontal layout in pet, poultry, ruminant, and aquaculture sectors [3] - Plans to enhance R&D and technological innovation to improve product competitiveness and optimize the product performance and industry chain structure [3] - The company aims to expand its overseas market presence, with a "going out" strategy to mitigate domestic business cycle impacts [3] Market Expansion - The company has established a veterinary drug production base in Vietnam and is obtaining production licenses [4] - In 2024, the export sales of raw materials increased by 155.71% year-on-year, with sales networks covering over 20 countries and regions [4] Industry Outlook - The veterinary drug industry is crucial for the healthy and stable development of the breeding industry, enhancing disease prevention capabilities and improving production efficiency [5] - The industry has seen continuous growth, with a compound annual growth rate of 8.47% in sales from 2019 to 2023 [5] - The market demand for veterinary drugs has rebounded since the second half of 2024 due to improved conditions in the breeding industry [5] Future Directions - The company plans to continue accelerating the approval and production efficiency of new drugs, focusing on innovative product development [6] - Emphasis on integrating R&D resources and enhancing collaboration with domestic and international enterprises in pet drug development [6] - The future direction includes a shift from "scale expansion" to "value enhancement," promoting high-quality development through technological innovation and green development [7]
回盛生物(300871) - 关于提前赎回“回盛转债”的第十一次提示性公告
2025-05-07 07:42
| 证券代码:300871 | 证券简称:回盛生物 | 公告编号:2025-047 | | --- | --- | --- | | 转债代码:123132 | 转债简称:回盛转债 | | 武汉回盛生物科技股份有限公司 关于提前赎回"回盛转债"的第十一次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、 误导性陈述或重大遗漏。 特别提示: 1、可转债赎回条件满足日:2025 年 4 月 17 日 2、可转债赎回登记日:2025 年 5 月 20 日 3、可转债赎回日:2025 年 5 月 21 日 4、可转债赎回价格:100.64 元/张(含息税) 10、根据安排,截至 2025 年 5 月 20 日(赎回登记日)收市后仍未转股的 回盛转债,将按 100.64 元/张(含税)的价格强制赎回。回盛转债二级市场价 格与赎回价格存在较大差异,特提醒回盛转债持有人注意在限期内转股。 11、投资者不符合创业板股票适当性管理要求的,不能将所持回盛转债转 换为股票,特提请投资者关注不能转股的风险。 12、风险提示:根据安排,截至 2025 年 5 月 20 日收市后仍未转股的回盛 转债,将按 ...